Featured Company News – Boston Scientific Outlined Sustained Growth Strategy; Set to Expand into New Markets and Product Portfolios

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Boston Scientific Corp. (NYSE: BSX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=BSX. Boston Scientific hosted a meeting with the investment community on June 27, 2017, in New York City, to deliver an overview of its business and long-term growth strategies. The CEO and Chairman, Mike Mahoney discussed the Company’s focus on expanding segment leadership and achieving growth globally in advanced patient care and delivering strong financial performance. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on BSX. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=BSX

Cardiovascular Segment

Boston Scientific announced that it continues to be the US leader in drug-eluting stents with its SYNERGY Bioabsorbable Polymer Drug Eluting Stent System for the treatment of coronary artery disease, and a global leader in products for complex percutaneous coronary interventions, intravascular ultrasound imaging, and chronic total occlusions.

The Company has additionally received the first ever Expedited Access Pathway (EAP) designation in peripheral by the US FDA for the study of a drug-eluting vascular stent system, administered for the treatment of critical limb ischemia below the knee. The EAP designation is currently reserved for breakthrough technologies that may offer a clinically greater edge over existing alternatives, and it is expected to accelerate the market approval of the drug-eluting vascular stent system designed for treatment of critical limb ischemia by about two years.

Rhythm Management Segment

Under this segment, Boston Scientific continues to deliver innovative technologies with global cardiac rhythm management portfolio approvals and launches. On June 27, 2017, the Company highlighted its Heartlogic™ Heart Failure Diagnostic4 that is part of the RESONATE™ family of cardiac resynchronization therapy defibrillator (CRT-D) devices, validated for detecting early indications of worsening heart failure.

MedSurg Segment

Boston Scientific recently announced that it invested in technologies to potentially enter $3.5 billion in new endoscopy markets, including endoluminal surgery for gastrointestinal cancer, which is emerging as an alternative to surgical resection of cancer or pre-cancer. The Company announced that it also plans to expand globally into the $2.6 billion urologic cancer segment.

Boston Scientific will present its pipeline of innovation in deep brain stimulation (DBS) for the treatment of movement disorders with patients that have Parkinson’s Disease, dystonia, and essential tremor, including the Vercise™ Gevia™ Deep Brain Stimulation System5, which recently received CE mark and is the industry’s first MR-conditional directional DBS system with stimulation visualization.

Company Growth Prospects

Currently, Boston Scientific delivers products to more than 24 million patients around the world, annually, and addresses global markets that are more than $40 billion today, and are expected to reach over $50 billion by 2020. The Company plans to launch new products into high-growth adjacent markets that are expected to address an incremental $13 billion in market opportunity by 2020. The Company plans to diversify its portfolio, away from low-growth markets to moderate and high growth markets, which represented 60% sales in 2016, with a goal to reach 75% of sales by 2020.

The Company additionally plans to achieve an organic revenue compound annual growth rate for 2018-2020 of 6% to 8% and consistent double-digit adjusted EPS growth, through ongoing operating margin improvement initiatives.

Last Close Stock Review

On Wednesday, June 28, 2017, the stock closed the trading session at $28.12, climbing 1.11% from its previous closing price of $27.81. A total volume of 20.24 million shares have exchanged hands, which was higher than the 3-month average volume of 6.99 million shares. Boston Scientific’s stock price surged 13.80% in the last three months, 29.23% in the past six months, and 25.82% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 30.00%. The stock is trading at a PE ratio of 89.84. At Wednesday’s closing price, the stock’s net capitalization stands at $38.58 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467095